Atlas Bio raises $11M in seed funding led by Creandum to scale its human biology data pipelines and accelerate partnerships with pharmaceutical sponsors.
Atlas Bio, a Berlin-based developer of an AI foundation model for in silico clinical trials, raised $11M in a seed funding round. The round was led by Creandum, with participation from First Momentum Ventures and LEA Partners. The company will use the funds to expand its engineering and scientific teams and enhance commercial partnerships. This funding brings total funding to $13.2M.
Who to call at Atlas Bio, and when
A new round usually means Atlas Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Atlas Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Atlas Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atlas Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Atlas Bio
Location
Germany
About
Atlas Bio is a Berlin-based developer of an AI foundation model for in silico clinical trials. The company creates AI-driven clinical evidence aimed at replacing traditional animal testing while accelerating drug development. It uses advanced technology to simulate Phase II clinical trial efficacy and discover alternative drug indications. Founded by Simon Romanski, Sebastian Bayer, and Dominik Hartl, Atlas Bio focuses on scaling human biology data pipelines and forming partnerships with pharmaceutical sponsors.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atlas Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
GermanyBiotechnologyArtificial IntelligenceTherapeutics